Current and Emerging Sleep Interventions for Older Adults with or without Mild Cognitive Impairment

IF 2 4区医学 Q1 Medicine

Current Treatment Options in Neurology Pub Date : 2024-09-04 DOI:10.1007/s11940-024-00808-4

Anastasia Suraev, Shawn Dexiao Kong, Zoe Menczel Schrire, Bonnie A. Tran, Nathan Cross, Elie Matar, Sharon L. Naismith

{"title":"Current and Emerging Sleep Interventions for Older Adults with or without Mild Cognitive Impairment","authors":"Anastasia Suraev, Shawn Dexiao Kong, Zoe Menczel Schrire, Bonnie A. Tran, Nathan Cross, Elie Matar, Sharon L. Naismith","doi":"10.1007/s11940-024-00808-4","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This systematic scoping review examines evidence from the last five years on sleep interventions in cognitive healthy older adults and those with mild cognitive impairment.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Sleep disturbance has been identified as a potential early, modifiable risk factor for dementia, making it crucial to investigate if these interventions also enhance cognitive function and neurodegenerative biomarkers.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Since 2019, research on sleep interventions in older adults with or without cognitive impairment has gradually expanded, especially on non-pharmacological treatments including CBT-I, exercise, and multi-modal interventions, which show promise but require further study to confirm cognitive benefits. Pharmacological interventions have primarily focused on melatonin and orexin antagonists, with long-term safety remaining a concern. Tailored, clinically effective interventions that consider the presence of Alzheimer’s disease biomarkers, such as amyloid, tau, cerebrovascular disease, or alpha-synuclein in key sleep-related circuits, are essential to developing feasible, cost-effective, and scalable treatments for older adults with or without cognitive impairment.</p>","PeriodicalId":10975,"journal":{"name":"Current Treatment Options in Neurology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11940-024-00808-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

This systematic scoping review examines evidence from the last five years on sleep interventions in cognitive healthy older adults and those with mild cognitive impairment.

Recent Findings

Sleep disturbance has been identified as a potential early, modifiable risk factor for dementia, making it crucial to investigate if these interventions also enhance cognitive function and neurodegenerative biomarkers.

Summary

Since 2019, research on sleep interventions in older adults with or without cognitive impairment has gradually expanded, especially on non-pharmacological treatments including CBT-I, exercise, and multi-modal interventions, which show promise but require further study to confirm cognitive benefits. Pharmacological interventions have primarily focused on melatonin and orexin antagonists, with long-term safety remaining a concern. Tailored, clinically effective interventions that consider the presence of Alzheimer’s disease biomarkers, such as amyloid, tau, cerebrovascular disease, or alpha-synuclein in key sleep-related circuits, are essential to developing feasible, cost-effective, and scalable treatments for older adults with or without cognitive impairment.

Abstract Image

查看原文本刊更多论文

针对有或没有轻度认知障碍的老年人的现有和新兴睡眠干预措施

综述目的本系统性范围界定综述研究了过去五年中关于睡眠干预对认知健康老年人和轻度认知障碍老年人的影响的证据。最新研究结果睡眠障碍已被确定为痴呆症的潜在早期可改变风险因素，因此研究这些干预措施是否也能增强认知功能和神经退行性生物标志物至关重要。摘要自2019年以来，有关对有或无认知障碍的老年人进行睡眠干预的研究逐渐增多，尤其是有关非药物治疗的研究，包括CBT-I、运动和多模式干预，这些方法显示出了前景，但还需要进一步研究以确认对认知的益处。药物干预主要集中在褪黑素和奥曲肽拮抗剂上，但长期安全性仍是一个令人担忧的问题。考虑到阿尔茨海默病生物标志物（如淀粉样蛋白、tau、脑血管疾病或关键睡眠相关回路中的α-突触核蛋白）的存在，量身定制临床有效的干预措施对于为有或无认知障碍的老年人开发可行、经济、可扩展的治疗方法至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Neurology CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of neurology. By presenting clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to the treatment of neurologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as epilepsy, headache, neurologic ophthalmology and otology, neuromuscular disorders, psychiatric manifestations of neurologic disease, and sleep disorders. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known neurologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.